ImmunoGen, Inc.  

(Public, NASDAQ:IMGN)   Watch this stock  
Find more results for IMGN
+0.19 (2.68%)
Feb 12 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.77 - 7.35
52 week 6.77 - 19.43
Open 7.24
Vol / Avg. 1.03M/1.16M
Mkt cap 650.79M
P/E     -
Div/yield     -
EPS -1.37
Shares 87.06M
Beta 1.88
Inst. own 91%
Apr 22, 2016
Q3 2016 ImmunoGen Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 8, 2016
ImmunoGen Inc at Cowen Health Care Conference - 9:20AM EST - Add to calendar
Feb 23, 2016
ImmunoGen Inc at RBC Capital Markets Healthcare Conference - 11:30AM EST - Add to calendar
Feb 10, 2016
ImmunoGen Inc at Leerink Partners Global Healthcare Conference
Jan 29, 2016
Q2 2016 ImmunoGen Inc Earnings Call - Webcast
Jan 29, 2016
Q2 2016 ImmunoGen Inc Earnings Release
Jan 12, 2016
ImmunoGen Inc at JPMorgan Healthcare Conference - Q&A Session
Jan 12, 2016
ImmunoGen Inc at JPMorgan Healthcare Conference
Dec 9, 2015
ImmunoGen Inc at Oppenheimer Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -184.30% -71.01%
Operating margin -156.55% -63.66%
EBITD margin - -57.21%
Return on average assets -49.62% -25.35%
Return on average equity - -109.63%
Employees 317 -
CDP Score - -


WALTHAM, MA 02451-1477
United States - Map
+1-781-8950600 (Phone)
+1-781-8950611 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


ImmunoGen, Inc. (ImmunoGen) is a clinical-stage biotechnology company focused on the development of targeted anticancer therapeutics. The Company's clinical and preclinical product candidates are antibody-drug conjugates (ADCs), which is a type of medicine that uses a monoclonal antibody to deliver a therapeutic agent to targeted cells. The Company has three clinical-stage anticancer compounds: mirvetuximab soravtansine (IMGN853), coltuximab ravtansine, IMGN529, and IMGN779. The Company's partners are Amgen Inc., Bayer HealthCare (a subgroup of Bayer AG), Biotest AG, Eli Lilly and Company (Lilly), Novartis Institutes for BioMedical Research, Inc. (Novartis), the Roche Group, Sanofi and Takeda. The Company's collaborative partner compounds include Kadcyla, Indatuximab ravtansine, Isatuximab, Anetumumab ravtansine, AMG 595, AMG 172, SAR566658, SAR408701, LOP628 and PCA062. All of the Company's compounds are ADCs with the exception of isatuximab, which is a therapeutic antibody.

Officers and directors

Stephen C. McCluski Independent Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Daniel M. Junius President, Chief Executive Officer, Director
Age: 63
Bio & Compensation  - Reuters
David B. Johnston Chief Financial Officer, Executive Vice President
Age: 60
Bio & Compensation  - Reuters
Ellie Harrison Chief Human Resource Officer, Vice President
Age: 60
Bio & Compensation  - Reuters
Richard J. Gregory Ph.D. Executive Vice President - Research, Chief Scientific Officer
Age: 57
Bio & Compensation  - Reuters
John M. Lambert Ph.D. Executive Vice President - Distinguished Research Fellow
Age: 64
Bio & Compensation  - Reuters
Charles Q. Morris Executive Vice President, Chief Development Officer
Age: 50
Bio & Compensation  - Reuters
Sandra E. Poole Senior Vice President - Technical Operations.
Age: 51
Bio & Compensation  - Reuters
Craig Barrows Vice President, General Counsel, Secretary
Age: 60
Bio & Compensation  - Reuters
Anna Berkenblit M.D. Vice President and Chief Medical Officer
Bio & Compensation  - Reuters